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Abstract
Background: The phenotypic and genetic heterogeneity of autism spectrum disorder (ASD) presents considerable
challenges in understanding etiological pathways, selecting effective therapies, providing genetic counselling, and
predicting clinical outcomes. With advances in genetic and biological research alongside rapid-pace technological
innovations, there is an increasing imperative to access large, representative, and diverse cohorts to advance
knowledge of ASD. To date, there has not been any single collective effort towards a similar resource in Australia,
which has its own unique ethnic and cultural diversity. The Australian Autism Biobank was initiated by the
Cooperative Research Centre for Living with Autism (Autism CRC) to establish a large-scale repository of biological
samples and detailed clinical information about children diagnosed with ASD to facilitate future discovery research.
Methods: The primary group of participants were children with a confirmed diagnosis of ASD, aged between
2 and 17 years, recruited through four sites in Australia. No exclusion criteria regarding language level, cognitive
ability, or comorbid conditions were applied to ensure a representative cohort was recruited. Both biological
parents and siblings were invited to participate, along with children without a diagnosis of ASD, and children who
had been queried for an ASD diagnosis but did not meet diagnostic criteria. All children completed cognitive
assessments, with probands and parents completing additional assessments measuring ASD symptomatology.
Parents completed questionnaires about their child’s medical history and early development. Physical
measurements and biological samples (blood, stool, urine, and hair) were collected from children, and physical
measurements and blood samples were collected from parents. Samples were sent to a central processing site
and placed into long-term storage.
Discussion: The establishment of this biobank is a valuable international resource incorporating detailed clinical
and biological information that will help accelerate the pace of ASD discovery research. Recruitment into this study
has also supported the feasibility of large-scale biological sample collection in children diagnosed with ASD with
comprehensive phenotyping across a wide range of ages, intellectual abilities, and levels of adaptive functioning.
This biological and clinical resource will be open to data access requests from national and international researchers
to support future discovery research that will benefit the autistic community.
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Background
Autism spectrum disorder (ASD) refers to a group of
complex and heterogeneous neurodevelopmental
conditions behaviourally defined by difficulties in
social communication, as well as restricted ranges of
interests and/or stereotypic/sensory behaviours [1].
Current prevalence estimates range between 1 and
1.7% of most surveyed populations [2–6], with males
more commonly diagnosed than females [7, 8]. Preva-
lence has risen sharply in the last two decades,
attributed largely to increasing awareness, changes in
diagnostic criteria, and increased diagnoses of individuals
with less severe symptom presentations [4, 9]. More than
70% of individuals diagnosed with ASD will also be
diagnosed with a medical (e.g. gastrointestinal, sleep,
metabolic condition) or psychiatric (e.g. depression,
anxiety) condition across their lifetime [10–12].
Estimated cognitive functioning and language levels
also vary considerably across individuals [13, 14].
The highly diverse phenotypic presentation in ASD is
also reflected in etiological heterogeneity, involving a
combination of genetic and environmental contributors.
Early research identifying specific genes responsible for
syndromes highly comorbid with ASD, such as fragile X
[15] and Rett syndrome [16], supported the role of de
novo variations of major effect. Studies of recurrence
risk in twin and family studies have also strongly sup-
ported the existence of heritable and polygenic risk fac-
tors. Heritability estimates, for example, have recently
converged at 83%, although significant variability in
these estimates have been reported [17–20]. Sequencing
studies have provided further support for the role of de
novo copy number variants, with increased rates in
individuals diagnosed with ASD, and their siblings,
compared to individuals without ASD. Replicated gene
discovery findings have started to converge on those
genes involved in regulation of early development and in
synaptic function [21]. It is also becoming increasingly
clear that these mutations appear amongst a background
of higher frequency of common variants that may account
for a significant proportion of liability in individuals
diagnosed with ASD. Converging evidence in this area
supports ASD as a complex polygenic condition with both
de novo and rare inherited variants acting amongst a
background of common genetic variation [22, 23].
Large and significantly collaborative bio-resources are
required to conduct discovery research, many of which
have been established within the last decade [24, 25]. A
few ASD-specific biobanks have been created, notably in
the USA and across several European countries, resulting
in significant and valuable advances in the field. The
Simons Foundation Autism Research Initiative (SFARI;
including the Simons Simplex Collection [26], Simons Vari-
ation in Individuals Project [27], and Simons Foundation
Powering Autism Research for Knowledge, SPARK),
the Autism Genetic Research Exchange (AGRE; [28]),
MSSNG, and the EU-AIMS Longitudinal European
Autism Project [29], are amongst the largest resources
that have been created, supporting genetic and
biological research to inform both diagnostic and
treatment discoveries. Alongside these collaborative
efforts have been rapid-pace advances in genomic
technology, such as high throughput genome sequen-
cing and advances in bioinformatic methods, that
have facilitated analysis incorporating thousands of in-
dividuals (e.g. [30]), as well as providing a mechanism
to identify extremely rare mutations or conditions.
Despite significant support from the autistic com-
munity for these large-scale genetic research efforts
[31], to date there has not been any attempt to create
such a resource in the Australian context. Australia
comprises a similar range of socio-demographic
variables relative to other international ASD biobanks,
but with a unique cultural and ethnic diversity. In
addition, many current ASD resources have specific
inclusion criteria pertaining to age, verbal or cognitive
ability (excluding minimally verbal individuals or
those with comorbid intellectual disability), or family
history (the Simon Simplex Collection, for example, is
restricted to families with only one known individual
diagnosed with ASD), limiting their potential
generalisability.
In 2013, the Cooperative Research Centre for Living
with Autism (Autism CRC; https://www.autismcrc.co-
m.au/) was established and is the world’s first national,
cooperative research effort focused on autism across
the lifespan. With the support of the Autism CRC, the
Australian Autism Biobank was created to house a
large repository of detailed phenotypic (observational
and reported clinical features) and biological informa-
tion from a broadly diverse and representative cohort
of children with ASD and their families. This reposi-
tory was later expanded to include several comparison
groups, including siblings of probands who do not
have a diagnosis of ASD, children recruited from the
general community without a diagnosis of ASD, and
children who had been clinically queried for an ASD
diagnosis, but who did not meet formal diagnostic cri-
teria. Data collection ceased on June 30th, 2018. The
aim of this protocol is to describe the study design and
data collection methods to support data access re-
quests from national and international researchers.
The long-term aim in establishing this biobank was to
develop a detailed biological and clinical resource to
significantly accelerate discovery genetic and biological
ASD research that will support earlier and more accur-
ate diagnostic efforts and facilitate more precise and
tailored interventions.
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Methods/design
Participants
The Australian Autism Biobank comprises four partici-
pant groups of children between two to 17 years of age:
(i) children diagnosed with ASD (‘ASD probands’); (ii)
children queried for ASD but who have not met DSM-5
diagnostic criteria for ASD (‘ASD-Query’); (iii) siblings of
children with ASD without an ASD diagnosis (‘siblings’);
and (iv) children without a diagnosis of ASD and no
first-degree relative diagnosed with ASD (‘controls’).
Where possible, both biological parents of ASD
probands/ASD-query children were invited to participate
to obtain complete family trios. A parent/primary care-
giver (hereafter referred to as ‘parent’, but including
non-biological parents, grandparents, or foster carers)
was required to provide written informed consent for all
children to participate in the study; children above the
age of 7 years could additionally provide written or ver-
bal assent to participate if their parent deemed them
cognitively able to understand the study requirements.
Probands had received a clinically confirmed diagnosis
of ASD per DSM-IV [32] or DSM-5 [1] criteria, depend-
ing on their age at diagnosis. A participant group was
also created to include children who had been queried
by a health professional for an ASD diagnosis, but did
not reach DSM-5 criteria for ASD, and who may also be
siblings of probands (‘ASD-Query’ participants). All
children with a diagnosis of ASD within a family were
invited to participate, where possible, including full and
half siblings and concordant/discordant twins. No exclu-
sion criteria were applied with respect to conditions
other than ASD (for example, other psychiatric, medical
or genetic conditions), cognitive function level, or
medication use. For all participants, sufficient English to
provide written informed consent (from parents) or
English spoken at home (for children) was required.
Settings
Participants were recruited through four sites/states in
Australia: (1) the Telethon Kids Institute, University of
Western Australia (Perth, Western Australia); (2) the Olga
Tennison Autism Research Centre, La Trobe University
(Melbourne, Victoria); (3) the University of New South
Wales (Sydney, New South Wales); and (4) Lady Cilento
Children’s Hospital (LCCH, Brisbane, Queensland). Each
site comprised of a principal research investigator, a post-
doctoral researcher and/or trained research officers for
data collection. Phenotypic and biological data collection
was conducted in clinical facilities at each site. Biological
samples were processed at the Institute for Molecular Bio-
science, University of Queensland (Brisbane, Queensland),
and stored in long-term biobanking facilities. All pheno-
type data collected on record forms were converted to an
electronic format, audited, and stored centrally.
Ethical approval for this study was provided by human
research ethics committees at Princess Margaret Hospital
for Children (2014029EP), La Trobe University (HEC16–
104), Sydney Children’s Hospital Network (14/SCHN/
269), Mater Health Services (14/MHS/212), the University
of Queensland (2014001079), and the University of
Western Australia (RA/4/1/8184).
Procedures
Standardised clinical assessments were conducted with
each child, including both parents where possible, and
involving a parent to facilitate completion of clinical
assessments with children where necessary. A reduced
set of these measures was obtained from siblings and
controls; see Fig. 1 for an overview of data collected
from each participant group.
Biological sample collection was attempted for all chil-
dren. As collection of blood samples can be distressing
for children, individual sites created tailored social
stories to facilitate understanding of the procedures
involved. Tailored instructions were also created for
parents to support collection of stool, urine, and hair at
home, for both trained and non-toilet trained children.
For unsuccessful home collections, a second collection of
these samples was attempted at the clinical appointment,
where possible. Blood, stool, and hair were immediately
shipped to the University of Queensland’s Institute for
Molecular Bioscience for initial processing, labelling, and
transfer to the biobanking facilities at Wesley Medical
Research. Urine samples were kept frozen at each site and
periodically shipped in batches on dry ice to the University
of Queensland’s Institute for Molecular Bioscience for
labelling and then transferred to long-term storage.
Clinical assessments and blood sample collections
were ideally conducted during one appointment, with
parents mailed out questionnaires and sample collection
kits prior to this appointment. In some cases, assess-
ments were split across multiple appointments, particu-
larly for families with several children participating,
those who were recruited as part of other research stud-
ies within data collection sites, or where children were
diagnosed at different times to their siblings. Research
staff attempted to follow up any missing data through
phone calls or emails to families. All clinical assessments
and questionnaires were checked and scored by individ-
ual sites. Reliability between research staff on clinical
assessments was maintained by each site. All hardcopy
de-identified questionnaires and assessments were en-
tered via a web-portal hosted on central servers.
Biological samples
Blood
Venous blood samples were collected by trained paediatric
phlebotomists or through hospital/pathology phlebotomy
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services. Samples were then transported at room
temperature to the University of Queensland’s Institute
for Molecular Bioscience and immediately processed (time
from collection to processing between 12 and 72 h).
EDTA (for DNA), SST (for serum), and PAXgene (for
RNA) tubes were used to collect blood from children and
parents (due to processing requirements, PAXgene
samples are only available for a selected number of
families). Collection of whole blood into EDTA tubes
was prioritised for the purposes of obtaining DNA.
Where a blood collection was unsuccessful (due to
child distress, difficulty obtaining a sample, or with-
drawal of parental consent), a saliva collection (2 ml
through spit or swab) was attempted.
Whole blood collected in EDTA or SST tubes were
stored at room temperature during transportation and
then centrifuged at 3000 rpm for 15 min to separate
the individual components of plasma, red blood cells,
buffy coat (EDTA) and serum (SST). Plasma, red
blood cells and serum were manually pipetted into
2 mL screw cap tubes for long-term storage at − 80
degrees Celsius. Buffy coats were added to a 50 ml
tube containing 25 mL 1 x TE (ph 8) and gently
inverted before re-centrifugation for a further 10 mins
at 3000 rpm. This washing step lyses contaminating
red blood cells that have been collected with the
buffy coat to effectively remove exposed haemoglobin;
known to interfere with the quality of extracted gen-
omic DNA.
Stool
Parents chose a method of stool collection best suited for
their child’s toileting level, either collected from a liner
suspended in a toilet bowl or scraped from diapers. Two
individual teaspoon stool samples were collected and sus-
pended in 4mLs RNAlater™. Samples were transported to
the University of Queensland’s Institute for Molecular
Bioscience and immediately processed (time from ship-
ping to processing 12–72 h). Each stool sample was vigor-
ously homogenised before being aliquotted into 3 × 1 mL
samples for long-term storage at − 80 degrees Celsius.
Urine
Parents chose a method of urine collection best suited
for their child’s toileting level, either as a mid-stream
collection, by a pipette from a toilet liner suspended in a
toilet bowl, from cotton balls placed in a nappy, or by
using a paediatric urine collection bag. Parents were
instructed to attempt to collect the first urination of the
morning, where possible, and freeze samples immedi-
ately. These frozen samples were then transported, with
frozen ice packs used to maintain temperature, by
families when attending their clinical assessments at
each site. Upon receipt, samples were immediately trans-
ferred to a − 80 °C freezer, noting condition of sample
upon receipt (frozen/not frozen, partially thawed, etc).
Samples were transferred in batches to the University of
Queensland’s Institute for Molecular Bioscience for
labelling and then transferred to long-term storage.
Fig. 1 Summary of data collected by participant group. Abbreviations. ADOS: Autism Diagnostic Observation Schedule, BAPQ: Broader
Autism Phenotype Questionnaire, CC-A: Communication Checklist – Adult, MSEL: Mullen Scales of Early Learning, SRS: Social
Responsiveness Scale, SSP: Short Sensory Profile, WASI: Wechsler Abbreviated Scale of Intelligence, WISC: Wechsler Intelligence Scale
for Children
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Hair
Hair samples, approximately 10 strands, were collected
at the base of the head, cut close to the scalp, without
the hair follicle. Samples were placed on aluminium foil
and transported at room temperature to the University
of Queensland’s Institute for Molecular Bioscience for
labelling, and then transferred to long-term storage.
See Table 1 for a summary of the biological samples
collected from each participant group.
Clinical phenotyping
ASD probands/ASD-query
ASD symptoms The Autism Diagnostic Observation
Schedule-2 (ADOS; [33]) is a semi-structured standar-
dised observational assessment designed to elicit
social-communication and repetitive behaviours relevant
to an ASD diagnosis, administered by researchers who
had obtained research-reliable coding. The most appro-
priate ADOS module was administered, based on the
participant’s age and current expressive language ability:
Module 1 (pre-verbal children with single words/simple
phrases), Module 2 (children with flexible phrase
speech), Module 3 (children or adolescents with fluent
language), and Module 4 (older adolescents with fluent
language). Behaviours are coded across five domains:
language and communication, reciprocal social inter-
action, play, stereotyped behaviours and restricted inter-
ests, and any other abnormal behaviours. Codes are then
scored to an algorithm to derive a standardised compari-
son score across modules, relative to age and/or language
ability; higher scores are indicative of greater ASD traits.
The Developmental, Dimensional, and Diagnostic
Interview (3di; [34]) is a computerised semi-structured
interview designed to support ASD diagnostic interviews
with minimal training and ongoing support. It was de-
veloped based on Autism Diagnostic Interview-Revised
(ADI-R; [35]) question formats and algorithm-based
symptom analysis with additional DSM-5 symptom
subscales. Interview questions relate to medical history,
language and non-verbal communication, play and
friendships, reciprocal social interaction, repetitive
behaviours and restricted interests, along with optional
sections on relevant childhood comorbidities. The inter-
view can be partially completed through questionnaires
or completed through an interview. The interview yields
both quantitative severity scores on diagnostic criterion
as well as number of criterion met.
Cognitive function Two cognitive measures were
administered, based on children’s chronological age. For
children between 2 and 6 years of age, the Mullen Scales
of Early Learning (MSEL; [36]) was used, which is a
standardised developmental assessment that incorpo-
rates interactive and play-based tasks. Four domains
were assessed: Fine Motor, Visual Reception, Expressive
Language, and Receptive Language. These four scales
were summed to yield an Early Learning Composite
Score, as an estimate of cognitive functioning (M = 100,
SD = 15). For each domain, raw scores, a corresponding
T-score, percentile rank, and an age equivalent, was
recorded. For children aged above 6 years, the Wechsler
Intelligence Scale for Children (WISC, 4th edition; [37])
was used, a standardised measure of cognitive function-
ing. Ten structured activities elicit cognitive abilities in
four domains: Verbal Comprehension, Perceptual
Reasoning, Working Memory, and Processing Speed.
These four domains sum to give a Full-Scale IQ estimate
(M = 100, SD = 15). Raw and scaled scores (relative to
chronological age) were recorded for each activity, along
with summed scaled scores, composite scores, percentile
rank and 95% confidence intervals for each domain.
Questionnaires As a measure of adaptive behaviour,
the Vineland Adaptive Behavior Scale was adminis-
tered (VABS, 2nd edition; [38]). This standardised and
norm-referenced measure was completed as a parent
questionnaire that assesses four domains of adaptive
behaviour: Communication, Daily Living Skills,
Socialization, Motor Skills (for children under 6 years
of age), that sum together giving an Adaptive Behavior
Composite score. Raw and scaled scores, percentile ranks,
and age-equivalents, were recorded for each domain
and sub-domain. Maladaptive behaviours were also
assessed, yielding a summary score of internalizing,
externalizing, and other maladaptive behaviours.
The Short Sensory Profile (SSP, 2nd edition; [39]) is a
34-item parent-reported measure of behavioural sensory
processing that assess difficulties with processing and
responding to sensory input. Parents rated a range of
behaviours on a scale of 1 (almost never) to 5 (almost
always), which sum to four subscales (Sensory Seeking,
Avoiding, Sensitivity, Registration) and two scales of
Sensory and Behavioural scores. Raw scores, percentile
Table 1 Biological samples collected by participant group
ASD-Probands/ASD-Query Parents Siblings/Controls
Blooda
EDTA 6 ml 10 ml 6 ml
SST 5 ml 5 ml 5 ml
PAXgeneb 2.5 ml 2.5 ml 2.5 ml
Stoolc 2 × 1 teaspoon – 2 × 1 teaspoon
Urinec ~ 20 ml – ~ 20 ml
Hairc ~ 10 strands – ~ 10 strands
aSaliva collection was attempted where a blood sample collection was
unsuccessful; bPAXgene samples (for RNA) collected on a sub-set of
participants; cStool, urine, and hair collected on a sub-set of children
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ranks, and rank relative to a normal distribution is
calculated.
The Children’s Communication Checklist (CCC, [40])
is a 70-item parent-reported measure that assesses
communication impairments relevant to both specific
language disorders and their overlap with ASD. The
CCC was completed as part of the 3di, administered
either as a questionnaire or during the interview. Items
are completed on a four-point scale (no, does not apply;
applies somewhat; definitely applies; unable to judge)
that sum to nine subscales related to pragmatic language
skills that are necessary for social communication. Five
of these scales sum to a pragmatic composite score.
Items were omitted for children with current expressive
language comprising only single words, and the ques-
tionnaire is not completed for children who are minim-
ally verbal or have no spoken language.
For any stool sample collections, parents additionally
completed the Australian Child and Adolescent Eating
Survey [41] to assess food frequency, usual food habits,
and nutrient intake over the previous six months. Energy
(kJ) and nutrient (protein, fat, carbohydrates, sugars,
fibre etc) intake was calculated based on parental
reports.
A bespoke family history questionnaire was designed
to capture medical history, pregnancy related factors
(e.g. stress or complications), early childhood develop-
ment, diagnostic history, current medication, sleep and
gastrointestinal function, as well as parental demograph-
ics and health.
Measurements Physical development was measured by
height, weight, and head circumference measurements.
The Tanner Stages [42, 43] was used to determine
physical pubertal development, where parents selected
descriptions of physical characteristics (genital, breast,
pubic hair development) to rate approximate pubertal
stage for children 8 years of age and above. Researchers
conducting the clinical assessment also assessed any
overt physical anomalies (fingers/hands, neck and spine)
and provided comments on behaviour during the clinical
assessment.
Siblings/controls
ASD symptoms The Social Responsiveness Scale (SRS,
2nd edition; [44]) is a questionnaire completed by par-
ents about autistic symptomology in children. It provides
a quantitative measure of autistic traits in clinical and
non-clinical samples and exhibits good reliability com-
pared to more comprehensive ASD diagnostic measures,
such as the ADI-R [45]. The SRS is a 65-item question-
naire rated on a 0 (never true) to 3 (almost always true)
scale that yields five subscales (social awareness, social
cognition, social communication, social motivation,
restricted and repetitive behaviours) and a total score.
The questionnaire also yields two DSM-5 relevant sub-
scales (social communication, restricted and repetitive
behaviours). Both raw and scaled T-scores were
calculated.
Cognitive function Based on the child’s age, the MSEL
[36] or the WISC 4th edition [37] was administered to
obtain a standardised measure of cognitive functioning.
Other questionnaires Parents completed the Australian
Child and Adolescent Eating Survey [41] once a stool
sample was collected. A family history questionnaire,
described above, was also completed.
Measurements The same physical measurements and
clinical ratings were also collected on siblings/controls.
Parents of ASD probands or ASD-query children
ASD symptoms The Broad Autism Phenotype Ques-
tionnaire (BAPQ; [46]) elicits personality and language
characteristics related to the ASD phenotype in parents
of individuals diagnosed with ASD. Thirty-six items are
self-reported on a 6-point scale (from very rarely applies
to applies very often) and summed to three subscales
(social behaviour, stereotyped-repetitive behaviour, and
communication).
Cognitive function The Matrix Reasoning subtest of
the Wechsler Abbreviated Scale of Intelligence (WASI,
2nd edition; [47]) was used as a measure of nonverbal
reasoning.
Other questionnaires The Communication Checklist –
Adult (CC-A; [48]) was developed as an adult extension
of the 2nd edition of the CCC [49] that assesses commu-
nicative behaviour. It is completed by an informant who
knows the individual well, in this case usually the other
person’s partner and/or parent of the child with ASD.
The questionnaire includes three subscales related to
language structure, pragmatic skills, and social engage-
ment. Previous research indicates the CC-A may be
sensitive in assessing the broader autism phenotype in
parents of children with ASD [50].
Measurements Height, weight, and head circumference
were also collected on parents at the time of blood
collection.
Parents of siblings or controls
For parents of siblings who were not biologically related
to the ASD proband(s), the BAPQ was also completed,
where possible. For parents of controls, both the BAPQ
and CC-A were completed.
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Database
All phenotypic (observational and parent-reported) data
was collected on hard copy record forms and entered re-
motely by each data collection site into databases hosted
centrally by Wesley Medical Research. Data officers per-
formed a 100% audit on all data entered for accuracy
against scanned copies of de-identified record forms.
Access
Ongoing management of this study is overseen by an
Operations Committee. Access to data can be requested
through an application to a Data Access Committee.
This committee includes representatives from the Aut-
ism CRC, researchers, and the autistic community. This
committee reviews any applications for phenotypic and/
or biospecimens stored in this biobank in compliance
with guidelines issued by the National Health and Med-
ical Research Council (NHMRC) under the National
Health and Medical Research Council Act 1992 and
guidance from the Autism CRC Board. Access to data is
subject to scientific review and a data access fee.
Discussion
Significant and rapid progress has been made into the
complex genetic, biological and interacting environmen-
tal mechanisms contributing to an ASD phenotype.
Alongside such advancements is the imperative for large
and well-characterised cohorts of participants diagnosed
with ASD from diverse and representative families. Sev-
eral successful international biobanks have supported
many scientific discoveries in this area to date, but have
collected limited amounts of clinical information,
restricted sample collection to saliva samples to favour
large-scale collection, or have imposed restrictive inclu-
sion criteria to allow for more homogenous participant
groups.
The Australian Autism Biobank is the first effort of its
kind in Australia, designed to overcome these previous
limitations by establishing an international resource that
will facilitate effective and timely research in this area.
While this biobank may not form the largest collection
of biological samples in ASD research, it is the only re-
source we are aware of to collect multiple biological
specimens alongside detailed ‘deep’ clinical phenotyping
[51] in a diverse sample. This data is being collected
from families with at least one child diagnosed with
ASD, incorporating a diverse range of clinical pheno-
types, as well as language and cognitive abilities, across
the childhood age range. Previous attempts to collect
blood for ASD genetic research alongside stool, urine, or
hair have been in much smaller numbers of selected
samples; the creation of this biobank provides, for the
first time, the opportunity to ask very detailed questions
about the potential interactions between genetic and
biological (metabolic, gastrointestinal, and other) mecha-
nisms underlying ASD. This biobank also specified a
minimal set of inclusion criteria, to allow for children
with a range of language and cognitive abilities to par-
ticipate; minimally verbal children, or those with comor-
bid intellectual disability, are often under represented or
are explicitly excluded participant groups in many
research protocols involving the collection of biological
samples. By keeping the inclusion criteria broad, this
biobank allows a unique diverse and representative sam-
ple cohort to support novel and replication research
questions that allows for the known heterogeneity of
ASD to be represented.
The addition of sibling and control comparison sam-
ples allows researchers to account for similar environ-
ments and shared genetic pathways. A significant
number of probands participating in this biobank are
also part of complex families with multiple children or
relatives diagnosed with ASD. For example, much of our
current understanding about ASD genetics comes from
the analysis and careful selection of families with
‘simplex’ histories (an absence of ASD diagnoses in
first-degree relatives); the inclusion of large and complex
multiplex families allows for the examination of novel
and testable hypotheses about inherited genetic varia-
tions of smaller effect [52]. The collective value of this
resource will not just be in the discovery of potential
novel genetic findings, but in the ability to combine
samples with other research groups to support essential
replication efforts to move the field forward.
To facilitate the success of this biobank, and ensure a
diverse and representative cohort was achieved, relation-
ships between individual data collection sites and
relevant health practitioners or organisations were estab-
lished, including paediatricians, clinical psychologists,
speech pathologists, diagnostic clinics, intervention
services, and disability organisations. Efforts were also
made to invite families from regional or remote areas of
Australia to participate where possible; for example, by
contributing only questionnaires and saliva samples via
mail, or by conducting clinical assessments during
weekends.
Practical considerations were made over the course of
the study that facilitated the completion of our aims.
One such step was to ensure protocols were in place to
successfully achieve biological sample collection for
most families, including very young children, those with
cognitive or language impairments, and those with
variability in toileting behaviours. Tailored social stories
for blood collection, pictorial collection instructions for
stool, urine, and hair samples, and creation of different
methods of sample collections based on levels of toilet
training, all facilitated better success rates in collections.
Other practical considerations included tailoring ID
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structures, questionnaire administration, and clinical
assessments for families, particularly those with multiple
children diagnosed with ASD.
In conclusion, the creation of this biobank has resulted
in a valuable international resource that will support
large-scale novel discovery ASD research. The specific
decision to include a diverse sample, with respect to age,
cognitive function, language ability, and adaptive func-
tion, from ethnically and culturally diverse populations
in Australia, has ensured that this resource will be able
to ask both novel questions and support replicability of
research findings from other established ASD repositor-
ies. Major genetic and biological advances have been
made over the last decade, and it is our hope that this
resource will further extend research in this area. The
detailed clinical information accompanying the bio-
logical samples also allows for a variety of questions to
be asked around clinical presentations, subtypes, and
patterns of traits within and across families at different
developmental periods. Importantly, the trust and sup-
port from families in contributing this data has been
vital, ensuring that this resource will remain an import-
ant and valued mechanism to support future discoveries
that will benefit the autistic community.
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